Newly Developed Modified ALBI Grade Shows Better Prognostic and Predictive Value for Hepatocellular Carcinoma
N/A (Source: Liver Cancer)
Source: Liver Cancer - December 8, 2021 Category: Cancer & Oncology Source Type: research
Bayesian Analysis Supports Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - December 8, 2021 Category: Cancer & Oncology Source Type: research
Radiologic response as a prognostic factor in advanced hepatocellular carcinoma with macroscopic vascular invasion after transarterial chemoembolization and radiotherapy
Introduction: We evaluated the radiologic response rate of combined transarterial chemoembolization (TACE) plus radiotherapy (RT) in treatment-na ïve patients with liver-confined hepatocellular carcinoma (HCC) with macroscopic vascular invasion (MVI) and analyzed its clinical importance in overall survival (OS) outcomes.
Methods: Patients who were treated with TACE plus RT as a first-line treatment for HCC with MVI between January 2010 and D ecember 2015 were retrospectively reviewed. Radiologic response was assessed according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST) at 2- and 4-months after ...
Source: Liver Cancer - December 7, 2021 Category: Cancer & Oncology Source Type: research
Evolution of Survival Impact of Molecular Target Agents in Patients with Advanced Hepatocellular Carcinoma
Conclusions: The availability of multiple MTAs had steadily improved the prognosis of patients with advanced HCC patients, particularly advanced-stage HCC patients.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - December 6, 2021 Category: Cancer & Oncology Source Type: research
Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma
Conclusion: Cabozantinib improved OS and PFS versus placebo at high and low baseline concentrations for all biomarkers analyzed. Low baseline levels of MET, HGF, GAS6, IL-8, and ANG2 and high levels of IGF-1 were identified as potential favorable prognostic biomarkers for survival in previously treated advanced HCC. Although cabozantinib promoted pharmacodynamic changes in several biomarkers, these changes were not associated with survival.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - December 3, 2021 Category: Cancer & Oncology Source Type: research
Treatments for the early stage Hepatocellular Carcinoma: Laparoscopic Liver Resection or Percutaneous Radiofrequency, How to make the decision?
Hepatectomy is still as the first-line treatment for the early stage HCC, but the complication rate is higher than p-RFA and the overall survival rate is comparable in these two treatments. Therefore, the patients with small single nodular HCCs could get more benefit from p-RFA, and we need to do further research about p-RFA. (Source: Liver Cancer)
Source: Liver Cancer - November 24, 2021 Category: Cancer & Oncology Source Type: research
Reply to Rizzo et al.
n.a. (Source: Liver Cancer)
Source: Liver Cancer - November 24, 2021 Category: Cancer & Oncology Source Type: research
First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials
Conclusion: Our simulation model provides a strong rationale to support ongoing trials evaluating second-line tyrosine-kinase inhibitors after first-line ATEZO plus BEVA. Future evidence from ongoing RCTs and prospective real-world studies are needed to prove the net health benefit of sequential treatment options for advanced HCC.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - November 23, 2021 Category: Cancer & Oncology Source Type: research
Pathological Complete Response to Lenvatinib After Failure of Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma
None (Source: Liver Cancer)
Source: Liver Cancer - November 15, 2021 Category: Cancer & Oncology Source Type: research
Regression of tumor thrombus in the suprahepatic vena cava of hepatocellular carcinoma and conversion hepatectomy induced by lenvatinib
We present the first case of advanced hepatocellular carcinoma with tumor thrombus in the suprahepatic vena cava clo se to the right atrium, which shrank after 12 weeks’ administration of lenvatinib, thereby leading to successful conversion surgery without using total vascular exclusion or extracorporeal circulation. The treatment strategy for hepatocellular carcinoma with macroscopic hepatic vein tumor thrombus is controversial, however, from a Japanese nationwide survey, surgical resection has been accepted as one of the treatment options for advanced hepatocellular carcinoma with hepatic vein tumor thrombus in Japan. ...
Source: Liver Cancer - November 11, 2021 Category: Cancer & Oncology Source Type: research
Contents Vol. 10, 2021
Liver Cancer 2021;10:I –VIII (Source: Liver Cancer)
Source: Liver Cancer - November 9, 2021 Category: Cancer & Oncology Source Type: research
Acknowledgement to Reviewers
Liver Cancer 2021;10:641 –642 (Source: Liver Cancer)
Source: Liver Cancer - November 9, 2021 Category: Cancer & Oncology Source Type: research
Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma
Conclusion: Our study suggests that the presence of all-grade irAEs may be a potential prognostic biomarker in patients with aHCC treated with ICI. Patients with more severe irAEs and multisystem involvement have better prognosis. The prompt use of systemic corticosteroids to treat patients with irAEs is key to ensure the best long-term outcomes for these patients.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - October 26, 2021 Category: Cancer & Oncology Source Type: research
A Novel Treatment Strategy for Patients with Intermediate-Stage HCC Who Are Not Suitable for TACE: Upfront Systemic Therapy Followed by Curative Conversion
Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - October 12, 2021 Category: Cancer & Oncology Source Type: research
Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma
Conclusions: Unlike other oncological indications, ATB in the 30 days before or after ICI initiation is associated with improved benefit from immunotherapy, independent of disease and treatment-related features. Evaluation of the immune microbiologic determinants of response to ICI in HCC warrants further investigation.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - October 8, 2021 Category: Cancer & Oncology Source Type: research
